Detalhe da pesquisa
1.
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
N Engl J Med
; 389(23): 2162-2174, 2023 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38055253
2.
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Lancet
; 403(10421): 31-43, 2024 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048793
3.
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
N Engl J Med
; 386(5): 437-448, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35045221
4.
Survival with Cemiplimab in Recurrent Cervical Cancer.
N Engl J Med
; 386(6): 544-555, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35139273
5.
Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab.
Oncologist
; 29(1): 25-35, 2024 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37523661
6.
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis.
Oncologist
; 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38716772
7.
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
N Engl J Med
; 385(20): 1856-1867, 2021 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34534429
8.
Photocatalytic Radical Coupling of Organoborates with α-Halogenated Electron-Poor Olefins.
J Org Chem
; 89(1): 633-643, 2024 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38079578
9.
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.
Int J Gynecol Cancer
; 2024 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38627035
10.
Incidence of sentinel lymph node metastases in apparent early-stage endometrial cancer: a multicenter observational study.
Int J Gynecol Cancer
; 34(5): 689-696, 2024 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38514100
11.
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 24(4): 392-402, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36878237
12.
The WID-EC test for the detection and risk prediction of endometrial cancer.
Int J Cancer
; 152(9): 1977-1988, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36533702
13.
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
Gynecol Oncol
; 172: 121-129, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37030280
14.
A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer.
Gynecol Oncol
; 178: 110-118, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37839313
15.
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.
Gynecol Oncol
; 175: 182-189, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37355448
16.
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
Gynecol Oncol
; 178: 119-129, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37862791
17.
Myeloid neoplasms post PARP inhibitors for ovarian cancer.
Int J Gynecol Cancer
; 33(4): 598-606, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36707087
18.
Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions.
Int J Gynecol Cancer
; 33(4): 431-443, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36928097
19.
Systemic therapy de-escalation in advanced ovarian cancer: a new era on the horizon?
Int J Gynecol Cancer
; 33(9): 1448-1457, 2023 09 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37597852
20.
Dose-dense neoadjuvant chemotherapy before radical surgery in cervical cancer: a retrospective cohort study and systematic literature review.
Int J Gynecol Cancer
; 2023 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37949488